[go: up one dir, main page]

BR0112800A - Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma - Google Patents

Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma

Info

Publication number
BR0112800A
BR0112800A BR0112800-0A BR0112800A BR0112800A BR 0112800 A BR0112800 A BR 0112800A BR 0112800 A BR0112800 A BR 0112800A BR 0112800 A BR0112800 A BR 0112800A
Authority
BR
Brazil
Prior art keywords
bile acid
treatment
prevention
plasma cholesterol
pharmaceutically acceptable
Prior art date
Application number
BR0112800-0A
Other languages
English (en)
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of BR0112800A publication Critical patent/BR0112800A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/785—Polymers containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

"UTILIZAçãO DE UM INIBIDOR DE LìPASES E DE UM SEQuESTRANTE DE áCIDO DE BìLIS FARMACEUTICAMENTE ACEITáVEIS E PROCESSO PARA A PREVENçãO E TRATAMENTO DE ENFERMIDADES ASSOCIADAS COM ALTOS NìVEIS DE COLESTEROL DE PLASMA". A presente invenção refere-se a um novo processo para a prevenção e tratamento de enfermidades associadas com altos níveis de colesterol de plasma, especialmente ao uso de um inibidor de lípases, por exemplo, orlistat, e um seq³estrante de ácido de bílis farmaceuticamente aceitável para o tratamento das enfermidades associadas com altos níveis de colesterol de plasma.
BR0112800-0A 2000-07-28 2001-07-19 Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma BR0112800A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP00116392 2000-07-28
PCT/EP2001/008353 WO2002009814A2 (en) 2000-07-28 2001-07-19 New use of lipase inhibitors

Publications (1)

Publication Number Publication Date
BR0112800A true BR0112800A (pt) 2003-07-01

Family

ID=8169383

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0112800-0A BR0112800A (pt) 2000-07-28 2001-07-19 Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma

Country Status (17)

Country Link
US (3) US6562329B2 (pt)
EP (1) EP1307263B1 (pt)
JP (2) JP4772264B2 (pt)
KR (1) KR100556324B1 (pt)
CN (1) CN1261094C (pt)
AR (1) AR031117A1 (pt)
AT (1) ATE293477T1 (pt)
AU (2) AU8969601A (pt)
BR (1) BR0112800A (pt)
CA (1) CA2416900C (pt)
DE (1) DE60110232T2 (pt)
DK (1) DK1307263T3 (pt)
ES (1) ES2240516T3 (pt)
MX (1) MXPA03000694A (pt)
PT (1) PT1307263E (pt)
WO (1) WO2002009814A2 (pt)
ZA (1) ZA200300454B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4772264B2 (ja) * 2000-07-28 2011-09-14 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害物質の新規用途
US20030027786A1 (en) 2001-06-06 2003-02-06 Karsten Maeder Lipase inhibiting composition
EP1413309B1 (en) * 2001-07-30 2007-11-14 Mitsubishi Pharma Corporation Drugs for ameliorating postcibal hyperglycemia
US20050276781A1 (en) * 2004-06-09 2005-12-15 Ross Edward A Molecularly imprinted phosphate binders for therapeutic use
KR101547925B1 (ko) * 2005-09-15 2015-08-27 젠자임 코포레이션 아민 중합체에 대한 샤셋 제형
US8067402B2 (en) * 2005-12-12 2011-11-29 Allaccem, Inc. Methods and systems for coating an oral surface
CA2648278C (en) * 2006-04-03 2019-05-28 Isa Odidi Drug delivery composition
ITRM20060204A1 (it) 2006-04-10 2007-10-11 Vincenzo Savica Farmaci e alimentei per diete normoproteiche iperproteiche ipopro teiche tutte ipofosforiche e bevande ipofosforiche
ZA200904573B (en) 2006-12-22 2010-09-29 Ironwood Pharmaceuticals Inc Compositions comprising bile acid sequestrants for treating esophageal disorders
ES2522908T3 (es) 2007-02-21 2014-11-19 Allaccem, Inc. Composiciones a base de compuestos policíclicos con puente para la inhibición y el alivio de enfermedades
US20090023682A1 (en) * 2007-07-19 2009-01-22 Joseph Artiss Composition Comprising Dietary Fat Complexer and Methods of Using Same
US8153617B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in humans
US8188068B2 (en) * 2007-08-10 2012-05-29 Allaccem, Inc. Bridged polycyclic compound based compositions for coating oral surfaces in pets
US8153618B2 (en) * 2007-08-10 2012-04-10 Allaccem, Inc. Bridged polycyclic compound based compositions for topical applications for pets
US20090074833A1 (en) * 2007-08-17 2009-03-19 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling bone resorption
US8524212B2 (en) * 2007-10-24 2013-09-03 Mitsubishi Tanabe Pharma Corporation Prophylactic and/or therapeutic drug for nonalcoholic steatohepatitis
US20100016270A1 (en) * 2008-06-20 2010-01-21 Whiteford Jeffery A Bridged polycyclic compound based compositions for controlling cholesterol levels
US20100004218A1 (en) * 2008-06-20 2010-01-07 Whiteford Jeffery A Bridged polycyclic compound based compositions for renal therapy
WO2009158625A2 (en) * 2008-06-26 2009-12-30 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing gastrointestinal disorders and gerd-related respiratory disorders
US20100008988A1 (en) * 2008-07-14 2010-01-14 Glenmark Generics, Ltd. Tablet compositions of amine polymers
CN101791296B (zh) * 2010-01-17 2012-08-29 山东新时代药业有限公司 一种奥利司他片剂及其制备方法
LT2568827T (lt) * 2010-05-14 2018-08-27 Omega Pharma Innovation & Development Nv Kompozicija, skirta dietinės mitybos riebalų absorbavimo mažinimui
WO2020213010A1 (en) * 2019-04-16 2020-10-22 Celagenex Research (India) Pvt. Ltd. Synergistic lipid controlling compositions
KR102271821B1 (ko) * 2020-12-18 2021-07-01 주식회사 엔테로바이옴 오를리스타트 및 아커만시아 뮤시니필라 eb-amdk19 균주를 포함하는 조성물
KR20230124947A (ko) * 2020-12-22 2023-08-28 사이토테릭스 인코포레이티드 담즙 전달 방법, 이에 사용하기 위한 조성물 및 키트
CN113057340B (zh) * 2021-04-29 2024-01-19 南京邮电大学 一种菌菇膳食纤维改性方法
WO2023023939A1 (en) * 2021-08-24 2023-03-02 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia
EP4161534B1 (en) * 2021-08-24 2024-11-06 Waterstone Pharmaceuticals (Wuhan) Co., Ltd. Polymers, compositions and methods for treating hyperuricemia

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
IT1190349B (it) * 1986-06-16 1988-02-16 Prodotti Formenti Srl Composizioni farmaceutiche ad attivita' sequestrante degli acidi biliari contenenti colestiramina quale principio attivo,e procedimento per prepararle
US5063210A (en) * 1989-04-20 1991-11-05 Lange Iii Louis G Use of sulfated polysaccharides to decrease cholesterol and fatty acid absorption
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5298497A (en) * 1990-05-15 1994-03-29 E. R. Squibb & Sons, Inc. Method for preventing onset of hypertension employing a cholesterol lowering drug
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US5616570A (en) * 1991-10-18 1997-04-01 Lange, Iii; Louis G. Use of non-absorbable synthetic sulfated polysaccharides to decrease cholesterol absorbtion
CA2098167C (en) * 1992-06-24 2006-12-19 Dorothea Isler Foodstuffs and feedstuffs containing a lipase inhibitor
CA2128044C (en) * 1993-08-05 2007-02-20 Klaus-Dieter Bremer Pharmaceutical compositions comprising a glucosidase and/or amylase inhibitor, and a lipase inhibitor
DE69633502T2 (de) * 1995-12-26 2006-02-23 Suntory Ltd. Procyanidin als den aktiven bestandteil enthaltende mittel gegen fettleibigkeit
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
CN1170534C (zh) * 1998-08-14 2004-10-13 霍夫曼-拉罗奇有限公司 含有脂酶抑制剂的药物组合物
JP3761783B2 (ja) 1998-08-14 2006-03-29 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害剤とキトサンを含む製薬学的組成物
GB9900416D0 (en) 1999-01-08 1999-02-24 Alizyme Therapeutics Ltd Inhibitors
HRP20030029B1 (en) * 2000-07-28 2005-06-30 F. Hoffmann - La Roche Ag New pharmaceutical composition
JP4772264B2 (ja) * 2000-07-28 2011-09-14 エフ．ホフマン−ラ ロシュ アーゲー リパーゼ阻害物質の新規用途

Also Published As

Publication number Publication date
US20030138396A1 (en) 2003-07-24
JP2009108062A (ja) 2009-05-21
DK1307263T3 (da) 2005-08-22
ZA200300454B (en) 2004-04-16
EP1307263A2 (en) 2003-05-07
KR20030069978A (ko) 2003-08-27
AR031117A1 (es) 2003-09-10
MXPA03000694A (es) 2003-06-04
CN1261094C (zh) 2006-06-28
US6562329B2 (en) 2003-05-13
ES2240516T3 (es) 2005-10-16
JP4772264B2 (ja) 2011-09-14
JP2004505066A (ja) 2004-02-19
ATE293477T1 (de) 2005-05-15
DE60110232D1 (de) 2005-05-25
US20020042395A1 (en) 2002-04-11
WO2002009814A2 (en) 2002-02-07
KR100556324B1 (ko) 2006-03-03
CA2416900A1 (en) 2002-02-07
AU2001289696B2 (en) 2006-07-06
AU8969601A (en) 2002-02-13
US20060189574A1 (en) 2006-08-24
CN1444496A (zh) 2003-09-24
DE60110232T2 (de) 2006-01-19
PT1307263E (pt) 2005-08-31
WO2002009814A3 (en) 2002-04-18
CA2416900C (en) 2007-07-03
EP1307263B1 (en) 2005-04-20

Similar Documents

Publication Publication Date Title
BR0112800A (pt) Utilização de um inibidor de lìpases e de um sequestrante de ácido de bìlis farmaceuticamente aceitáveis e processo para a prevenção e tratamento de enfermidades associadas com altos nìveis de colesterol de plasma
MX9702204A (es) Tratamiento con ribozimas de enfermedades o condiciones relacionadas con niveles de lipoproteina (a) [lp(a)] en plasma, inhibiendo apolipoproteina (a) [apo(a)].
BR9813767A (pt) Processo e composição para tratar glaucoma de glc1a
BR0206639A (pt) Combinações de inibidor(es) da absorção do esterol com modificador(es) do sangue para o tratamento de condições vasculares
MXPA02009327A (es) Lente de contacto que tiene un perfil de espesor horizontal uniforme.
BR0112799A (pt) Composição farmacêutica, processo para preparação e utilização da mesma, conjunto e processo para tratamento de obesidade, utilização de um inibidor de lìpase e de um sequestrante de ácido de bìlis e processo de tratamento ou prevencão de efeitos colaterais gastrointestinais
AU3396597A (en) Combination of acid protease enzymes and acidic buffers and uses thereof
DE60016461D1 (de) Verfahren zur behandlung von glassubstraten und glassubstraten zur herstellung von anzeigeschirmen
EP2444810A3 (en) Proteases mutants with altered specificity and uses thereof
ATE292959T1 (de) Verfahren zur herstellung von pankreasenzym enthaltende mikrosphären mit hoher stabilität
BR9307718A (pt) Variante de lipase ou de &-amilase, processo de estabilização de uma lipase ou de uam &-amilase em relação à inativação causada por um sistema peroxidase, composição detergente e aditivo detergente
BR9916486A (pt) Combinações de inibidores do transporte de ácidos biliares no ìleo e inibidores da proteìna de transferência do ester colesteril para indicações cardiovasculares
EP1007556A4 (en) TROPONIN SUB-UNITS AND FRAGMENTS FOR USE AS INHIBITORS OF ANGIOGENESIS
BR9712824A (pt) Composição oftálmica de fator neurotrófico, agente de tratamento de desordem funcional do nervo ótico e método para tratamento de desordem funcional do nervo ótico
TW200504078A (en) Therapeutically active compounds and their use
BR9914940A (pt) Método para aperfeiçoar a farmacocinética de tipranavir
AU2002363182A1 (en) Smad7 inhibitors for the treatment of cns diseases
BRPI9814894A (pt) processo para a preparação de ácidos 8-metóxi-quinolonocarboxílicos.
PT808898E (pt) Reagente e metodo para inibicao da expressao de n-ras
TW268937B (pt)
EP0930067A3 (en) MMP inhibitors for the treatment of ocular angiogenesis
MX9601368A (es) Metodo de tratamiento de la reestenosis por terapia genica.
BR9712705A (pt) Composição para o tratamento da asma, contendo loratadina e um descongestionante
WO1998032846A3 (en) Enzymatic nucleic acid treatment of diseases or conditions related to levels of c-fos
BR9914848A (pt) Composição e processo para o tratamento de distúrbios da retina externa

Legal Events

Date Code Title Description
B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]
B15K Others concerning applications: alteration of classification

Ipc: A61K 31/16 (2006.01), A61P 3/06 (2006.01), A61K 31